October 27, 2016

Summit Call Recap – October 13, 2016
Information from CDC
Announcements

SUMMIT CALL RECAP – OCTOBER 13, 2016


Influenza Surveillance Update – Stacy Davlin (CDC)

Because the first report for the 2016–2017 influenza season will not be released by CDC until tomorrow (October 14), Stacy was unable to provide that report to the Summit. Therefore, she reviewed highlights of the previous report from week 39, ending October 1, 2016. This is the final week of reporting for the 2015–2016 season.

Influenza activity in the U.S. continues to remain low. Clinical lab percent positives have increased slightly in the past week, with 2.2% of specimens submitted found to be positive. Influenza A viruses were most common during week 39, with influenza A (H1N1) predominating.

The proportion of deaths from P&I based on reports for week 39 from the 122 Cities Mortality Reporting System was 5.69%, slightly below the epidemic threshold of 5.75%. Mortality due to P&I was 5.59% in the NCHS. As of this week, the 122 Cities Mortality Reporting System is being retired; NCHS will now be the primary source of data for P&I mortality.

No additional influenza-associated pediatric deaths was reported to CDC during the week, with a total of 85 pediatric deaths reported during the 2015–2016 season. Of the 71 for whom vaccination status was known, 5 were ineligible for vaccination due to age and 18 were fully vaccinated according to ACIP recommendations.

At 1.3%, influenza-like illness (ILI) activity remained below the national baseline of 2.1% for the week.


CPT Coding for Flucelvax – L.J Tan (IAC)

L.J reported that some providers (including pediatric providers) who have replaced previously used supplies of FluMist with Flucelvax (Seqirus) have encountered difficulty obtaining payment for this vaccine using CPT code 90674. The FDA approved quadrivalent Flucelvax in May, 2016, and CPT code 90674 was issued and published by the AMA on July 1. Typically, the AMA CPT group allows a 6-month grace period before actual implementation of a code. The AMA has released the following statement:

 

CPT code 90674 was released electronically on July 1, 2016 for implementation on January 1, 2017. Payers can implement the code based on a beneficiary’s needs any time after the code’s release on July 1.

L.J noted that some, but not all, payers have adopted code 90674 and have been reimbursing for it.

On September 30, 2016, CMS included the additional information on this issue in Transmittal 3617.  All reimbursements will be issued back to August 1, 2016. However, the same document states that, due to some technical issues, full implementation of reimbursement cannot occur until January 3, 2017. Seqiris asked CMS for clarification, and they have issued instructions to the Medicare Administrative Contractors (MACs) to either (1) pay claims from August through December in January or (2) develop a “Not Otherwise Classified” (NOC) code for that period to provide payment sooner. Unfortunately, some providers are now reporting that many regional CMS payers have delayed implementation until January and have not provided any workaround for this issue.

The Summit is trying to create awareness about this payment problem. In addition, Summit partners are requested to send an email to L.J Tan to report any issues they are having receiving payment for this vaccine. This will help us gain perspective on how extensive this issue is for providers.


Other Items – L.J Tan (IAC)
  • The 2017 National Adult and Influenza Immunization Summit is scheduled for May 9–11, 2017 in Atlanta, GA. Updates and registration information will be added to the website as they become available.
  • Richard Besser from ABC News will moderate a discussion about influenza prevention and the upcoming season on Twitter via @abcDrBchat. In addition, @CDCFlu will be participating in the chat and is encouraging health care providers, partner organizations, and the general public interested in fighting influenza to join the conversation at 1:00 p.m. on Tuesday, October 18 by following the hashtag #abcDrBchat!

INFORMATION FROM CDC


CDC COCA Webinar on Influenza

On October 27 CDC held a COCA webinar entitled What’s New for the 2016–2017 Flu Season: Recommendations for Children.  The CDC site contains archived slides and recordings from the webinar, as well as information on how to earn free continuing education credits.


Updated CDC Information on Influenza

CDC’s influenza talking points from October 21, 2016 and the FluView report for Week 41 (ending October 15) are now available online.

 


Reports from October ACIP Meeting

The ACIP October 2016 meeting was held last week. Please see these websites for excellent summaries of the meeting’s discussions and votes:


CDC NetConference on HPV Vaccine Recommendations

On October 26 CDC hosted a Current Issues in Immunization NetConference, Recommendations for HPV Vaccination, 2016 Update. The archived conference is now available online.


ANNOUNCEMENTS


NFID Announces Upcoming Presentations

On November 16 NFID will be hosting a free CME/CNE webinar covering updates from the October 2016 ACIP meeting, including updated recommendations for adults, children, and adolescents.  A brief description of the webinar and registration information are available online. Presenters for the webinar will be William Schaffner, MD, NFID Medical Director and NFID liaison to the Advisory Committee on Immunization Practices (ACIP) and NFID Secretary, Patricia Stinchfield, MS, CPNP, CIC, Senior Director, Infection Prevention & Control and Pediatric Nurse Practitioner, Infectious Disease/Immunology at Children’s Minnesota and current liaison member to ACIP.

Other upcoming NFID events include:


IAC Publishes New Edition of Vaccinate Adults

The Immunization Action Coalition (IAC) has released the latest edition of its informative publication, Vaccinate Adults. This abbreviated version contains the adult-related immunization information found in IAC’s sister publication, Needle Tips.


Article on Factors Associated with Abandonment of Zostavax Vaccine

Check out this interesting article paper on the factors impacting abandonment of zoster vaccine from the American Journal of Pharmacy Benefits.

 

Print Friendly, PDF & Email